We have used an anti-human polymeric immunoglobulin receptor (pIgR) single chain Fv (scFv) to deliver reporter genes to epithelial cells in vitro. The scFv was constructed from a monoclonal antibody directed against pIgR and a cysteine residue was added at the carboxyl end to facilitate its conjugation to polylysine (polyK) via the heterobifunctional cross-linker SPDP. ScFv-cys was expressed in Drosophila S2 cells and purified to homogeneity using conventional column chromatography. ScFv-polyK, and polyK as control, were condensed with a DNA expression plasmid containing the luciferase reporter gene driven by the CMV promoter into unimolecular (with respect to DNA) complexes under high salt conditions. Target cells were MDCK cells transfected with human pIgR and repeatedly sorted for highlevel receptor expression, with untransfected MDCK cells as
Introduction
Cystic fibrosis (CF) is an autosomal recessive genetic disorder due to a defect in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR), and affects many organs. 1 However, the major cause of morbidity and mortality is from the pulmonary manifestations. Therefore, the respiratory epithelium is the primary target for gene therapy in CF. Receptor-mediated gene therapy has great appeal for this purpose, because it affords access to the appropriate cells and appears to be safe. In addition, it allows flexibility in size and sequence of the DNA. The human polymeric immunoglobulin receptor (pIgR) 2 is expressed at high levels in the airway epithelium, in most of the cell types that express CFTR in the human airway. 3 It is adapted for non-degradative bulk transfer, and can be accessed for gene transfer in vitro and in vivo. In previous studies, 4, 5 we targeted the pIgR to deliver genes in vitro in the human tracheal epithelial cells and in vivo to the receptorbearing organs of rats. In earlier studies we used the Fab fragment of an anti-pIgR antibody as a ligand, which was covalently linked to polylysine, and complexed with various expression plasmids. This system successfully delivered reporter genes to tracheal epithelial cells and sub- control. Receptor-bearing MDCK cells were readily transfected by scFv-cys containing, pIgR directed complexes, and expression could be blocked by addition of excess human secretory component (SC), the extracellular portion of pIgR. In contrast, MDCK cells that did not express pIgR were not transfected. Nontargeted complexes were not effective in transfecting MDCK cells with or without pIgR. Targeted complexes also transfected human tracheal epithelial cells in primary culture, corroborating the pIgR-mediated gene delivery. These data indicate that a scFv directed against human pIgR can direct foreign genes specifically into receptor-bearing cells in vitro. We have expressed and purified a ligand that is efficient and specific in pIgR-mediated gene delivery. Gene Therapy (2001) 8, 586-592.
mucosal glands of rats and mice, although expression only lasted 12 days. The Fab used in these studies was generated from anti-pIgR antibody by an enzymatic reaction which was cumbersome and had obvious disadvantages. Moreover, the Fab proved to be immunogenic on repeated administration. 6 Therefore, we speculated that using a recombinant scFv as a ligand instead of Fab would help us circumvent these problems. The scFv is the smallest portion of the antibody that contains the antigen-binding site. 7 It consists of the amino terminal variable domains of the light chain (V L ) and the heavy chain (V H ) linked together by a peptide. This recombinant molecule can be produced in substantial amounts and in a relatively purified form. However, it is essential first that the scFv constructed bind to the receptor, be taken up appropriately, and in a model system in vitro, function as a ligand in gene delivery to pIgR-expressing epithelial cells. We report here the construction of a scFv ligand which can access this receptor specifically in culture.
Results
Expression of a recombinant anti-human pIgR scFv in Drosophila Schneider 2 (S2) cells Figure 1 shows Western analysis of the media from different Drosophila S2 clones developed using anti-his6 antibody. In addition to the expected 29 kDa band representing the scFv-cys, an additional band at 75-80 kDa was noted, which was also found in the medium alone (data not shown), suggesting that it is a protein present in the medium that contains a stretch of multiple histidine residues. The clone shown in lane 6 ( Figure 1 ) was chosen for expression and purification of the scFv-cys protein.
Purification of scFv-cys
Transfected Drosophila S2 cells were grown in hygromycin B containing medium for 10 days to allow expression and accumulation of the protein in the medium. Medium was applied to a Ni 2+ agarose column. In the eluant fractions ( Figure 2a, lanes 3-6) , there is a 29 kDa band representing the scFv-cys, but the contaminant protein of MW 75-80 kDa (identified in Figure 1 ) appears to be copurified by the Ni 2+ agarose column. Therefore, the eluted fractions from the Ni 2+ agarose column were applied to a Sephacryl S-100 column. Several fractions Gene Therapy from this column display a single band at 29 kDa (Figure 2b ). These fractions were pooled and used in the following experiments. Silver stained gel ( Figure 2c ) and a Western blot using anti-his6 antibody (Figure 2d ) of the purified protein indicate that the scFv-cys protein is purified to homogeneity. About 50 g of purified scFv-cys was obtained from 250 ml of media.
Functional analyses of scFv-cys
We examined the ability of the purified scFv-cys to interact with the pIgR in two ways. In an ELISA assay with capture by secretory component (SC), the soluble portion of pIgR (Figure 3) , scFv-cys interacts with secretory component in a dose-dependent manner. As a second and more rigorous method for examining functional activity, we performed a transcytosis assay. The parental IgG from which the scFv was generated is transported from basolateral to apical surface in a highly specific fashion. Basolateral to apical transport is inhibited by excess human secretory component (hSC), but not rat (rSC) or monkey (mSC), even in five-fold molar excess, a concentration of human SC sufficient to reduce transcytosis by more than 80% (Figure 4 ). Apical to basolateral transport is less than 20% of basolateral to apical transport in all cases (data not shown). In this assay about 15% of scFv-cys is transported from the basolateral to the apical surface of a monolayer of MDCK cells expressing pIgR ( Figure 5 ). Thus, the scFv-cys expressed and purified from Drosophila S2 cells is able to bind to pIgR and be transported by it.
EM analyses of the scFv-polyK-DNA complexes From our previous studies 4, 5, [8] [9] [10] on gene delivery we have noted that condensed DNA carrier complexes were efficient in transfection. We examined the complexes used in this study by EM to assess the compaction. The constituents of the complex were studied separately and appeared to have entangled masses of strand-like structures. We measured electron micrographs of 20 particles from each of four complexes that were made independently. Compacted complex appeared to be roughly spherical in shape and 25 (±7) nm in size ( Figure 6a ). We also examined the nontargeted complexes, which were spherical and 18 (±4.5) nm (Figure 6b ).
Transfection of the MDCK pIgR cells or primary human tracheal epithelial cells using scFv-polyK carrier
An expression plasmid CMV Luc containing the firefly luciferase was used as the reporter gene to monitor the efficiency of transfection. This plasmid can be efficiently delivered to cells using the lipofectin method of transfection (5.2 million light units of luciferase activity/mg protein). MDCK cells lacking the receptor transfected with scFv-polylysine-DNA complex had 0.05 million light units of luciferase activity/mg protein whereas in MDCK pIgR cells luciferase expression was 0.6 million light units/mg protein (Ͼ10-fold more than the cells without receptor) (Figure 7 ). Transfection is blocked in receptor-bearing MDCK cells with 10-fold molar excess of soluble receptor (secretory component, SC) to 0.04 million light units of luciferase whereas luciferase 
Figure 7 Luciferase expression in transfected cells. (a) MDCK (filled bars) or MDCK pIgR (grey bars) cells grown on rat tail collagen matrix were transfected with targeted (scFv/Fab) or non targeted complexes (W/o lig), or with targeted complex incubated with a ten-fold molar excess of human SC (scFv/Fab+SC). Points are the mean from eight experiments, except for the Fab experiments which are the mean of three experiments. (b) Primary human tracheal epithelial cells were grown on collagen gel matrix, were treated with scFv-containing complexes (lig) or non targeted complexes (W/o lig). Points are the mean of three experiments.
expression in MDCK cells lacking the receptor could not be blocked significantly. This indicates that the transfection in the MDCK cells without receptor by scFv-polylysine-DNA may be a nonspecific event. The nontargeted complex made with polylysine and CMVLuc DNA did not transfect either the MDCK or the MDCK pIgR cells. Our previous studies were done using anti-SC Fab from polyclonal rabbit antibodies as ligand, for gene transfer. 4, 5 In this study we compared Fab and scFv from a single monoclonal antibody with regards to their efficiency in gene transfer to MDCK or MDCK pIgR cells. Transfection by complexes prepared with Fab (0.17 million integrated light units/mg protein) was far less efficient than transfection by complexes prepared with scFv (0.6 million integrated light units/mg protein) in MDCK pIgR cells. Moreover, Fab containing complexes delivered transgene to the cells with similar efficiency irrespective of receptor expression. Figure 7a shows combined results of eight separate experiments, except for the Fab-containing complexes, which are from three experiments. We also tested the ability of the scFv-based complexes to transfect primary epithelial cells grown on collagen gels, which display native pIgR expression. These cells, too, showed receptor-specific transfection (Figure 7b ). Taken together, these observations indicate that gene transfer in the MDCK pIgR cells occurs by a specific uptake of the scFvpolylysine-CMVLuc complex through the receptor.
The time-course of luciferase expression in the cells is shown in Figure 8 . The maximum level of luciferase activity was detected after 24 h (0.85 million integrated light units/mg protein) and luciferase activity of cells decreased to ෂ5% on the 5th day after transfection (Figure 8a ). The cells were transfected when they were 40-50% confluent and continued to grow throughout the experiment. To test whether cell growth might have diluted the integrated light units of luciferase expression per miligram of protein, we also expressed the luciferase activity as integrated light units of luciferase per well (Figure 8b ). When expressed in this way, the levels of luciferase expression remained high for 5 days and then declined precipitously to near background by day 7.
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Discussion
A recombinant scFv, directed against human pIgR, was expressed in Drosophila S2 cells, and purified to homogeneity using Ni 2+ column and molecular exclusion chromatography. By sandwich ELISA and transcytosis assay, we have shown that the recombinant scFv can bind efficiently to the pIgR and be transported across an epithelial monolayer bearing pIgR from the basolateral to the apical surface. Although less scFv undergoes transcytosis than parental IgG, the IgG has two binding sites for the receptor compared to one in scFv, so the actual efficiency of scFv in transcytosis was comparable to that of IgG. These binding studies indicate that the scFv can bind to the pIgR in the context of the cell and be handled in a physiological manner. However, efficiency in transcytosis cannot be equated with efficiency in gene transfer. When pIgR is internalized, about 70-75% of the receptors undergo transcytosis but about 25-30% of them are recycled to the basolateral surface. If the cycling route results in prolonged intracellular retention of the receptor and its cargo, this might allow more time for endosomal escape of the complex and favor gene transfer.
DNA encoding the luciferase gene complexed to antipIgR scFv poly-l-lysine conjugate was specifically and efficiently transfected into MDCK cells bearing pIgR. The following lines of evidence suggest that the gene transfer by this method is receptor mediated. First, MDCK cells without receptor were transfected much less efficiently (90% less) by scFv-poly-l-lysine-luc complexes. Second, nontargeted complexes that lacked the scFv ligand could not transfect in pIgR containing MDCK cells. Finally, transfection of luciferase reporter gene by the scFv-polyl-lysine could be inhibited over 90% by addition of SC, the soluble portion of the pIgR receptor. Although we did not test competition by the natural ligand for this receptor, dimeric IgA, directly in this assay, it is unlikely to compete for several reasons. The antibody from which this scFv was cloned was selected for its ability to bind to IgA as well as SC, precisely to avoid competition with the natural ligand. An antibody which binds to SC after it is bound to IgA almost surely binds at a different site compared with the natural ligand. Moreover, Ferkol and coworkers have shown that a fusion protein prepared with this scFv is not prevented from transcytosis by even a 100-fold molar excess of dimeric IgA. 11 Several features of our gene transfer complexes, especially the ease of expression and purification of a recombinant receptor ligand of high affinity and specific targeting of the receptor by the gene transfer complex, are quite promising for gene therapy. However, some features of the expression from this complex require improvement. First, although gene transfer was specific and moderately high level 1-2 days following transfection, expression fell rapidly in cultured cells. Although some of this apparent loss of expression is attributable to dilution of luciferase activity, calculated as integrated light units/mg protein, by cell growth in culture, duration of expression in culture is still less than it is for expression directed by the serpinenzyme complex receptor (sec-R). [8] [9] [10] In the sec-R system, protracted expression was obtained with complexes prepared with long-chain (ෂ256 residues) polylysine, whereas expression was much shorter in duration with complexes of identical chemical composition prepared with shorter chain polylysine (ෂ36 residues). One notable difference between the short chain and long chain complexes was their diameter, measured by electron microscopy. In the present study, the complexes (all prepared with long chain polylysine) were about 25-30 nm in diameter, larger than the sec-R directed complexes made with long chain polylysine which were 17 ± 0.9 nm. It is possible that the much larger size of the protein ligand in the present study (about 29 kDa as opposed to about 2 kDa for the sec-R ligand) prevented tight compaction of the plasmid DNA with the polylysine, either by steric hindrance or by chemical interference. These larger complexes might lead to shorter duration of expression. Alternatively, differences in intracellular trafficking between pIgR directed complexes and secR directed complexes might also account for the differences in duration of expression. Therefore, continued manipulation of the construction of the complex, to minimize particle size, might improve duration of expression.
Although our earlier successful gene transfer studies directed at the pIgR utilized Fab fragments from polyclonal rabbit antibodies directed against pIgR (rat or human), Fab fragments from this monoclonal antibody did not produce receptor-specific gene transfer. Complexes prepared with Fab fragments did transduce MDCK cells somewhat better than nontargeted complexes, but this was true whether or not the cells expressed pIgR. We suspect that the physical form of the complex was more favorable for nonspecific uptake than non-Fab-containing complexes. However, the ligand did not target the receptor specifically. When Fab containing complexes are prepared, coupling to SPDP-polyK takes place through cysteine residues in the Fab. Such coupling might disturb the binding conformation of the Fab fragment. For the scFv, we engineered a free C-terminal cysteine residue, which is probably favored for the disulfide exchange reaction with SPDP. Addition of protein at this site does not affect the binding properties of the scFv (for example, the scFv fusion protein with alpha1-antitrypsin retains full capacity of the scFv to bind to the receptor). Thus, the scFv was superior to the Fab fragments from the same antibody for receptor-specific gene transfer in these experiments.
It will also be important to test immunogenicity of the scFv in vivo. Although most species-specific sequences have been removed in scFv compared with the parent Fab, there remain short stretches of framework region that are species specific and may therefore be immunogenic. In addition, this protein might be immunogenic in the context of the complex even if it is not especially immunogenic by itself. All of these possibilities must be tested empirically.
It is also crucial to test these complexes in vivo. However, this scFv does not recognize the pIgR of any nonhuman species, including primate. This makes it difficult to test efficiency in vivo, which is the most important test for any gene transfer system. Mice will need to be genetically engineered to express the human pIgR in order to complete such testing.
Nevertheless, the appeal of receptor-targeted gene delivery is strong, and for a disease such as cystic fibrosis, where the airways disease and thick mucus provide formidable barriers to approach the epithelium from the airway lumen, approaching from the blood has advantages. This strategy should also allow targeting of the submucosal glands, where CFTR expression is normally high. The data reported here indicate that the redesigned receptor ligand has promise for gene transfer.
Materials and methods
Construction and expression of anti-human pIgR scFvcys The c-DNA for anti-human pIgR scFv cloned from 4121 monoclonal antibody, was modified using a 3′ primer with additional codon for cysteine preceding the stop codon and KpnI restriction sites at both 5′ and 3′ ends to facilitate ligation and subcloning. In addition to the scFvcys sequence, the cDNA included an Ig-k chain leader sequence for secretion in eukaryotic cells and six histidine residues for detection and purification. The leaderhis6-scFv-cys construct was subcloned into pPac 12 vector under Drosophila actin 5C promoter for constitutive expression. The pPac scFv-cys construct was cotransfected with pPac hygromycin into Drosophila S2 cell line using Cellfectin transfection reagent (Life Technologies, NY, USA) according to the manufacturer?s protocol. Stable cell lines were generated by selection with Hygromycin B for 2 weeks followed by soft agar cloning. The colonies were picked from soft agar, grown in Hygromycin B containing media, and screened for expression of scFv-cys.
Purification of scFv-cys
Medium of expressing S2 cells was dialyzed against 50 mm phosphate buffer pH 8.0 and bound to Ni-NTA agarose (Qiagen, Valencia, CA, USA) equilibrated with the same buffer. After washing twice with 50 mm phosphate buffer (pH 8.0) containing 0.3 m NaCl and 20 mm imidazole, the scFv-cys was eluted using the same buffer with 250 mm imidazole. Eluted proteins were analyzed using SDS-PAGE and by Western blot procedure. The active fractions were pooled, dialyzed against 50 mm phosphate buffer (pH 7.0) and 0.15 m NaCl, and passed through Sephacryl S-100 column (Amersham Pharmacia Biotech, Piscataway, NJ, USA). The active fractions were identified by SDS-PAGE and Western blot using either anti-His6 antibody (Calbiochem, La Jolla, CA, USA) or donkey anti-mouse antibody (Jackson Immunoresearch, West Grove, PA, USA) and concentrated using concentrators (Millipore, Bedford, MA, USA).
Preparation of anti-SC Fab fragments
Fab antibody fragments were prepared from anti-SC monoclonal antibody by methods described previously. 4, 5 ELISA and transcytosis assay For functional analysis of scFv-cys, purified protein at different concentrations was incubated in microtiter plates coated with human secretory component, and bound protein was detected by horseradish peroxidase (HRP)-conjugated donkey anti-mouse antibody (Jackson Immunoresearch). Purified anti-pIgR IgG, the parent antibody for the scFv, was used for standardization.
For transcytosis assay, purified scFv-cys or IgG was added to the culture medium either on the apical (0.3 ml) or basolateral (0.5 ml) side of confluent MDCK pIgR cells grown on filters with 1 m pores (Beckton Dickinson, Franklin Lakes, NJ, USA). MDCK culture medium was placed on the opposite side. After incubation at 37°C for Gene Therapy 24 h media were collected, dialyzed against PBS, concentrated to a third of the original volume and analyzed by ELISA using the same HRP donkey anti-mouse antibody.
Preparation of scFv-polyK conjugates Purified scFv-cys was conjugated to poly-l-lysine, MW 53 kDa (Sigma Chemical Co, St Louis, MO, USA) using the heterobifunctional crosslinker SPDP. Poly-l-lysine was mixed with SPDP in a molar ratio of 20:1 in PBS and incubated at room temperature, in the dark for 30 min. The SPDP-polyK mixture was then dialyzed against water for 48 h to remove excess unreacted SPDP. This procedure results in SPDP modifications of 5% of the lysine residues.
9 The SPDP-PolyK was then mixed with scFv-cys in a 20:1 molar ratio and incubated at room temperature in the dark for 48 h. This scFv-polyK conjugate was used for preparing scFv-polyK-DNA complexes.
Preparation of scFv-polyK-DNA complexes The scFv-polyK-DNA complexes were prepared using the techniques described previously. 8, 13 Plasmid DNA (CMV-luciferase) was condensed by slow addition (10 l/5 min) of scFv-polyK conjugate in 600 mm NaCl, under constant vortexing at room temperature. Sufficient conjugate was added so that the positive charges of the polylysine would neutralize the negative phosphate groups on the DNA. During the course of addition the solution appeared turbid due to aggregate formation. Aggregates were titrated with small additions of 5 m NaCl to achieve a condensed state unimolecular with respect to DNA, and the turbidity cleared. The final concentration of NaCl was typically between 0.9 m and 1.1 m. As control, DNA was condensed in the same manner with unconjugated polyK (53 kDa). Aliquots of each condensed mixture were analyzed by electron microscopy, to assess the condensation.
Preparation of Fab-polyK-DNA complexes Fab-polyK conjugate and Fab-polyK-DNA complexes were prepared following the same procedure as those used for preparing scFv-polyK-DNA complexes.
Cell and cell culture Drosophila S2 cells were grown on Drosophila Schneider medium (Life Technologies) with 10% FBS, 50 g/ml gentamicin, 0.25 g/ml of amphotericin B, 100 units/ml of penicillin and 100 g/ml of streptomycin.
The MDCK cells and MDCK cells transfected with pIgR were cultured in Eagle's minimum essential medium (BioWhittaker, Walkersville, MD, USA) supplemented with 10% FBS, 2 mm l-glutamine, 15 mm N-2 hydroxymethyl piperazine-N′ ethane sulfonic acid, 100 units/ml penicillin and 100 mg/ml of streptomycin. Cells stably transfected with pIgR were repeatedly sorted for the highest level of pIgR by fluorescence-activated cell sorting using anti-human SC (Sigma, St Louis, MO, USA), followed by fluorescein isothiocyanate-conjugated secondary antibody as previously described. 11 Human tracheal epithelial cells were harvested from necropsy specimens and grown as described previously. 5 Transfection of cells MDCK cells, MDCK cells transfected with pIgR or primary human tracheal epithelial cells were grown on rattail collagen matrix to about 40-50% confluency. Growth medium was withdrawn and replaced with media containing either scFv-polyK-DNA complexes or polyK-DNA complexes, equivalent to 4 g of DNA per transfection. This concentration of DNA for transfection was selected as optimal based on preliminary dose-ranging studies. The medium containing complexes was washed with PBS and replaced by growth medium after 30 min. Also, simultaneously, lipofectin was used to transfect the CMV luciferase DNA, to demonstrate the ability of these cells to express the plasmid.
Assay for luciferase
Harvested cells were homogenized in 50 l lysis buffer (Promega, Madison, WI, USA) incubated for 15 min at room temperature and centrifuged at 12 000 g for 15 min. Ten microliters of the supernatant were analyzed for luciferase activity as described in Ref. 14 and normalized for protein content assayed by Bradford method (Biorad, CA, USA). Results shown are expressed as integrated light units/mg of protein unless otherwise mentioned.
Electron microscopy (EM) of condensed DNA complexes Micrograph grids were prepared as described previously. 13 Briefly, immediately after complex preparation, a drop of solution was added to a 1000 mesh EM carbon grid (Ted Pella, CA, USA), blotted and stained with 0.04% uranyl acetate. After rotary shadowing, the grids were examined using a JEOL-100C electron microscope.
